期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 99, 期 12, 页码 4940-4954出版社
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.22217
关键词
biopharmaceutics classification system (BCS); bioequivalence; oral absorption; developability; biorelevant media; solubility; permeability; dissolution rate
A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the in vivo performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to in vivo performance than the widely used BCS. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:4940-4954, 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据